Lymphoseek: Final Phase III data

Final data from the open-label, U.S. and Israeli Phase III NEO3-05 trial showed that Lymphoseek met the primary endpoint of a 97.7% concordance rate with vital blue dye in 215 nodes. Lymphoseek also i...